OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
Patients with moderate to severe plaque psoriasis showed meaningful improvements in skin, itch and quality-of-life measures among PASI 75 non-responders treated with OTEZLA, according to a post hoc sub-analysis of data from the phase 3 ESTEEM 1 trial
Findings suggest a broad assessment of skin lesions, itching and quality of life may offer meaningful benefit with OTEZLA therapy in patients with moderate to severe plaque psoriasis
A separate post hoc sub-analysis of data from the phase 3 ESTEEM 1 and 2 and phase 4 UNVEIL trials showed improvement in areas such as the scalp and nails with OTEZLA versus placebo
These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).
Beware of fraudulent and misleading emails being sent by unauthorized persons for job interviews/offers at Celgene Corporation. These messages are being sent to cheat individuals. Celgene never requires any payment to be made by any candidate to Celgene or to any individual or agency as part of our recruitment process. Celgene will never ask for bank account or credit card information pre-hire. Please report any such activity to Frank Marrero.